Helius Medical Announces Results from a Case Series of Subjects with Advanced MS
NEWTOWN, Pa.-- Helius Medical Technologies, Inc. (TSX: HSM, HSM.S, OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce the results of a case series of individuals with advanced symptoms of Multiple Sclerosis (MS) treated with PoNS™ Therapy.
This study was performed at TCNL1, University of Wisconsin, Madison and the data was presented at the 2016, Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).
Six subjects with advanced MS (Expanded Disability Status Scale (EDSS)2 scores ranging from 6.5 to 7.5) were enrolled in a six-month pilot study. Subjects were trained in PoNS™ Therapy which combines use of the prototype PoNS™ device with physical training in balance, gait, movement and postural stability. Results demonstrated improvements in physical, cognitive and quality of life parameters. The demanding training regimen also resulted in significant real life improvements such as re-adopting a walker for community mobility, decreased fatigue, increased independence with daily activities, overcoming physical obstacles at home and increased community access.
Read more: Helius Medical Technologies Inc ( HSM )
Published: 21 June 2016
Written by Editor